In an early anti-CAIX CAR-T clinical trial, Lamers et al. tested a first-generation G250 CAR-T comprised of a single CD3ζ costimulatory domain in metastatic ccRCC patients [13–15]. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.